OWC Pharmaceutical Research Corp. (OTCQB: OWCP) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.

Just after the closing bell on Friday, October 14th, 2016, OWCP released an 8-K (see it here).  That 8-K states the following very important sentence:

The Registrant is reporting in this Form 8-K that effective on October 3, 2016, the Registrant has no convertible debt outstanding whatsoever.

Translation: No Death Spiral / Toxic Financing like many OTC traded companies.

In addition to the confirmation of no toxic financing, it was less than a month ago they announced:

effective as of September 22, 2016 pursuant to which Medmar has agreed to loan OCW Ltd a total of $300,000 on a non-interest bearing basis, with no conversion rights. Medmar agreed to fund the Loan in six equal installments of $50,000 each. To date, OWC Ltd. has received $100,000 of the total Medmar loan commitment.

So, OWCP is clearly sittin’ pretty on financing.

Market Potential for Products:

Again, I’ll repeat from the previous post:  If a couple of other Pink Sheet stocks with 2 Billion and 5 Billion Outstanding Shares can post losses (one of them in the multi-millions) and still have a Market Value of $16 Million to $48.7 Million… Then why, oh, why wouldn’t OWCP (with a list of positives that prove it’s a superior) be capable of reaching $0.40/share ($40M Market Value) in the near future?


Credit: Some of the content here was brought forth by ‘John Kent‘ on iHub